1 |
J.P. Skelly, G.A. Van Buskirk, DR Savello, G.L. Amidon and et ai., Scale-up and immediate release oral solid dosage forms,.Phann. Res., 10, 313-16 (1993)
DOI
|
2 |
FDA, Federal Register, 59, 48754-48759 (1994)
|
3 |
FDA, Center for Drug Evaluation and Research, SUPAC-IR questions and answers to SUPAC-IR guidance, February 1997
|
4 |
FDA, Center for Drug Evaluation and Research, Guidance for Industry: SUPAC-IRIMR: Immediate release and modified release solid oral dosage forms; Manufacturing equipment addendum, January 1999
|
5 |
일본국립의약식품위생연구소(National Institute of Health Sciences), Division of Drugs, Guideline for bioequivalence studies for formulation changes of oral solid forms, February 2000
|
6 |
식품의약품안전청고시 제 2002-60호 '생물학적동등성시험 기준' 제 3조 제 4항
|
7 |
식품의약품안전청고시 제 2002-60호 '생물학적동등성시험 기준' 제 3조 제 5항
|
8 |
M. Cho, J Kim, H. Lee and H. Sah, Understanding of f mettics used to evaluate similarity of dissolution profiles, J. Kor. Pharm. Sci., 33, 245-253 (2003)
|
9 |
FDA, Center of Drug Evaluation and Research, Guidance for Industry-Changes to an approved NDA or ANDA, November 1999
|
10 |
FDA, Department of Health and Human Services, Supplements and other changes to an approved application, Federal Register, 64, 34608-34625 (1999)
|
11 |
FDA, Center for Drug Evaluation and Research, Guidance for Industry-Immediate release solid oral dosage forms: Scale-up and postapproval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, November 1995
|
12 |
FDA, Center for Drug Evaluation and Research, Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, August 2000
|
13 |
J.A. Cook, Industrial experience with the BCS guidance in NDA: Value and limitations, AAPS Workshop on Biopharmaceutics Classification System: Implementation Challenges and Extension Opprotunities, Arlington, VA, September 2002
|
14 |
FDA, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research & Center for Veterinary Medicine, Guidance for Industry: Comparability protocolschemisty, manufacturing, and controls information, February 2003
|